PE22-28 UK Research Peptide for Advanced TREK-1 Applications
PE22-28 UK research peptide is one of the most extensively studied TREK-1 inhibitor compounds within neurogenesis, synaptic-plasticity and neuroregulation research literature. At Lavish Peptides, we supply premium-quality PE22-28 peptide products for laboratory and in vitro research applications throughout the United Kingdom and Europe, including London, Manchester, Birmingham, Liverpool, Leeds, Glasgow, Edinburgh, Dublin, Paris, Berlin, Amsterdam, Madrid, Milan and Rome.
PE22-28, also known as Mini-Spadin, is a synthetic 7-amino-acid peptide derived from Spadin (PE12-28), a naturally occurring peptide generated through sortilin cleavage. Scientific investigations have identified PE22-28 as one of the most potent and selective TREK-1 potassium-channel inhibitors currently available for laboratory research, demonstrating dramatically improved affinity and in vivo stability compared with its parent compound Spadin.
Research literature has characterised PE22-28 as an optimised Spadin analogue specifically engineered to improve TREK-1 channel binding, bioavailability and experimental utility. Published investigations documented that PE22-28 demonstrated an IC₅₀ of approximately 0.12 nM against TREK-1 channels compared with 40–60 nM for Spadin, establishing PE22-28 as the preferred peptide tool for TREK-1 pathway research and neurogenesis studies.
Scientific investigations have additionally demonstrated that PE22-28 selectively inhibits TREK-1 without significant interaction with related K2P potassium channels including TREK-2, TRAAK, TRESK or TASK-1. Research literature further documented that TREK-1 modulation influences serotonergic signalling, hippocampal neurogenesis, synaptic-plasticity pathways and neuronal excitability, making PE22-28 one of the most important research peptides within modern TREK-channel pharmacology.
Each PE22-28 UK peptide vial supplied by Lavish Peptides is produced according to strict laboratory-focused standards and supplied as a lyophilised powder in sealed laboratory-grade vials designed to support product integrity during transport and storage. Every batch undergoes third-party HPLC analytical verification procedures to support high purity and consistency expectations for laboratory and analytical applications.
Researchers throughout England, Scotland, Ireland, Germany, France, Spain, Italy, the Netherlands, Belgium, Austria, Portugal and wider Europe increasingly seek trusted peptide suppliers capable of combining premium sourcing standards with dependable fulfilment procedures and discreet shipping services. Lavish Peptides continues supporting laboratories and neuroscience researchers throughout the UK and Europe with premium peptide compounds and professional customer support.
Researchers interested in exploring additional premium peptide compounds can also browse our full peptide collection through the Lavish Peptides online catalogue.
Premium PE22-28 UK Laboratory Standards
At Lavish Peptides, quality assurance remains central to every peptide product supplied throughout the UK and Europe. Every PE22-28 UK batch undergoes third-party HPLC verification procedures designed to support analytical purity and consistency expectations for laboratory and in vitro research use.
The peptide is supplied within sealed amber laboratory vials intended to help minimise unnecessary environmental exposure during transport and storage. Orders are processed using discreet packaging and secure fulfilment procedures for customers throughout London, Manchester, Birmingham, Glasgow, Edinburgh, Paris, Berlin, Amsterdam, Madrid and Milan.
Researchers throughout England, Ireland, France, Germany, Spain and Italy continue seeking reliable peptide suppliers capable of delivering premium-quality TREK-1 research compounds with dependable shipping and transparent fulfilment standards. Lavish Peptides remains committed to supporting peptide researchers throughout Europe with premium peptide products and responsive customer support.
As neurogenesis and potassium-channel research continue expanding internationally, laboratories increasingly prioritise suppliers with strong quality-control standards and reliable fulfilment operations. Our objective is to provide premium peptide sourcing for research-focused customers across the UK and European peptide market.
Scientific Interest in PE22-28 UK Research
PE22-28 UK research continues receiving substantial attention within peptide-science literature and laboratory investigations involving TREK-1 inhibition, hippocampal neurogenesis and synaptic-plasticity pathway analysis.
Research involving PE22-28 has discussed:
- TREK-1 potassium-channel inhibition
- Hippocampal neurogenesis and synaptogenesis
- Serotonergic signalling modulation
- Neuroplasticity and cognitive-function research
- Stress-response and corticosterone-model studies
- Seizure-resistance pathway investigations
- Post-stroke depression and ischemia models
- Comparative Spadin and TREK-1 analogue research
Published scientific investigations have demonstrated that PE22-28 selectively blocks TREK-1 channels with extremely high affinity and specificity. Research literature additionally documented that PE22-28 displays markedly improved potency relative to Spadin while retaining rapid-onset behavioural effects and strong neurogenic activity within pre-clinical models.
Scientific literature has additionally confirmed that TREK-1 overexpression is associated with depressive-like phenotypes in animal models, while genetic TREK-1 deletion produces resistance to depression-related behavioural states. Published studies therefore identified TREK-1 as a highly promising research target distinct from conventional monoamine-based mechanisms.
Several investigations have examined PE22-28 within hippocampal neurogenesis and cognitive-function research. Studies documented increased synaptogenesis, enhanced neurogenesis biomarkers and improvements in spatial-memory and short-term recall tasks following PE22-28 treatment within controlled laboratory models.
Research literature has further explored PE22-28 within post-stroke depression and seizure-resistance investigations. Published studies demonstrated modulation of depressive markers in ischemia-associated models while additionally showing increased resistance to generalised seizures despite theoretical concerns associated with TREK-1 inhibition.
Scientific investigations additionally documented important applications for PE22-28 within anxiety-pathway analysis, serotonergic signalling research and comparative nootropic peptide studies. Research also explored selectivity comparisons between PE22-28, Spadin and alternative TREK-channel modulators within advanced neurobiology frameworks.
Research institutions and peptide laboratories throughout London, Dublin, Berlin, Stockholm, Copenhagen, Vienna and Amsterdam continue exploring advanced neuroregulation compounds within controlled scientific environments. Interest in TREK-1 peptides and neuroplasticity-pathway compounds continues increasing throughout the UK and European scientific sector as laboratories seek advanced molecules for receptor and pathway analysis.
For researchers seeking additional peptide information and fulfilment experiences, our customer testimonials provide insight into the standards and customer experience offered by Lavish Peptides throughout the UK and Europe.
UK and European Peptide Delivery
Lavish Peptides provides fast and discreet shipping for PE22-28 UK peptide products throughout England, Scotland, Wales, Northern Ireland, Ireland, France, Germany, Spain, Italy, Belgium, Austria, Portugal, Sweden, Denmark, Poland and the Netherlands.
Researchers throughout London, Manchester, Liverpool, Birmingham, Leeds, Glasgow, Edinburgh, Paris, Berlin, Amsterdam, Madrid, Milan and Rome continue relying on secure peptide fulfilment services and dependable delivery standards when sourcing laboratory compounds online.
Every PE22-28 UK order is packaged carefully to support customer privacy and maintain product integrity throughout transportation. Our fulfilment procedures are designed to support laboratories and research-focused customers seeking efficient peptide sourcing across Europe.
Researchers interested in additional premium peptide compounds may also wish to explore our Selank peptide product available through the Lavish Peptides research catalogue.
Storage and Handling Recommendations
PE22-28 UK research peptides should be handled according to appropriate laboratory handling standards and storage procedures. Researchers commonly store lyophilised peptide compounds in cool, dry environments away from direct sunlight and unnecessary temperature fluctuations.
Maintaining controlled storage conditions may help preserve peptide integrity during laboratory and analytical applications. Proper laboratory procedures should always be followed during preparation, handling and peptide research activities.
Lavish Peptides recommends reviewing internal laboratory protocols and safe handling standards before working with peptide compounds within laboratory environments.
Why Researchers Choose Lavish Peptides
Lavish Peptides continues establishing itself as a trusted supplier within the UK and European peptide market by focusing on premium sourcing, third-party verification and professional fulfilment standards.
Researchers choose Lavish Peptides for:
- Premium research-grade peptide sourcing
- Third-party HPLC-verified purity
- Fast UK dispatch
- Discreet packaging
- Reliable EU shipping
- Secure checkout experience
- Responsive customer support
- Laboratory-focused fulfilment standards
Our objective is to provide premium peptide compounds for laboratory and analytical use throughout Europe while maintaining dependable customer support and strict quality expectations.
For laboratory and in vitro research use only. Not for human consumption. Not a medicine.
Reviews
There are no reviews yet.